The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study

AIDS

Volumn 26, Issue 13, 2012, Pages 1691-1705

  Cain, Lauren ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

efavirenz; HIV; marginal structural models; mortality; nevirapine; observational studies

Indexed keywords

CD4 ANTIGEN; EFAVIRENZ; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; DRUG EFFECT; DRUG TREATMENT FAILURE; EUROPE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT OUTCOME; UNITED STATES;

ADULT; ANTI-HIV AGENTS; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HIV REVERSE TRANSCRIPTASE; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; NEVIRAPINE; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84865504746     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328354f497     Document Type: Article

References (21)

1. World Health Organization. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. http://www.who.int/hiv/pub/arv/rapid- advice-art.pdf. 2009.
2. European AIDS Clinical Society. EACS Guidelines http://www. europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/eacsguidelines-v6- english.pdf. 2011.
3. Gazzard BG, Anderson J, Babiker A, Boffito M, Brook G, Brough G, et al. 1; British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008; 9:563-608.
4. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. http://www.aidsinfo. nih. gov/Content Files/AdultandAdolescentGL.pdf: Department of Health and Human Services; 2011.
5. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 304:321-333.
6. Mbuagbaw LCE, Irlam JH, Spaulding A, Rutherford GW, Siegfried N. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals. Cochrane Database Syst Rev 2010; 12:CD004246.
7. Phillips AN, Pradier C, Lazzarin A, Clotet B, Goebel FD, Hermans P, et al. Viral load outcome of nonnucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients. AIDS 2001; 15:2385-2395. (Pubitemid 34014607)
8. Cozzi-Lepri A, Phillips AN, d'Arminio Monforte A, Piersantelli N, Orani A, Petrosillo N, et al. Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I. Co. N. A. ) study. J Infect Dis 2002; 185:1062-1069. (Pubitemid 34297764)
9. Matthews GV, Sabin CA, Mandalia S, Lampe F, Phillips AN, Nelson MR, et al. Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. AIDS 2002; 16:53-61. (Pubitemid 34062182)
10. Keiser P, Nassar N, White C, Koen G, Moreno S.Comparison of nevirapine-and efavirenz-containing antiretroviral regimens in antiretroviral-naive patients: a cohort study. HIV Clin Trials 2002; 3:296-303. (Pubitemid 34830680)
11. Potard V, Rey D, Mokhtari S, Frixon-Marin V, Pradier C, Rozenbaum W, et al. First-line highly active antiretroviral regimens in 2001-2002 in the French Hospital Database on HIV: combination prescribed and biological outcomes. Antivir Ther 2007; 12:317-324. (Pubitemid 46787976)
12. Nachega JB, Hislop M, Dowdy DW, Gallant JE, Chaisson RE, Regensberg L, Maartens G. Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults. AIDS 2008; 22:2117-2125.
13. Hartmann M,Witte S, Brust J, Schuster D,Mosthaf F, Procaccianti M, et al.Comparison of efavirenz and nevirapine in HIV-infected patients (NEEF Cohort).Int J STD AIDS 2005; 16:404-409. (Pubitemid 40868375)
14. The Antiretroviral Therapy Cohort Collaboration. Rates of disease progression according to initial highly active antiretroviral therapy regimen: a collaborative analysis of 12 prospective cohort studies. J Infect Dis 2006; 194:612-622.
15. The HIV-CAUSAL Collaboration. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS 2010; 24:123-137.
16. CDC. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morb Mortal Wkly Rep 1992; 41:1-19.
17. Cain LE, Robins JM, Lanoy E, Logan R, Costagliola D, Hernán MA. When to start treatment? A systematic approach to the comparison of dynamic regimes using observational data.Int J Biostat 2010; 6:Article 18.
18. Cole SR, Hernán MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol 2008; 168:656-664.
19. Manosuthi W, Sungkanuparph S, Tantanathip P, Lueangniyomkul A, Mankatitham W, Prasithsirskul W, et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitorbased regimens in HIV-infected patients receiving rifampicin: the N2R Study. Clin Infect Dis 2009; 48:1752-1759.
20. Swaminathan S, Padmapriyadarsini C, Venkatesan P, Narendran G, Kumar R, Iliayas S, et al. Once-daily nevirapine vs. efavirenz in the treatment of HIV-infected patients with TB: a randomized clinical trial. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, February 8-11, 2009.
21. van den Berg-Wolf M, Hullsiek KH, Peng G, Kozal MJ, Novak RM, Chen L, et al. Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons. HIV Clin Trials 2008; 9:324-336.